PYY1 36
Alternative Names: PYY1-36Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator AdiTech Pharma
- Class Obesity therapies; Peptide hormones
- Mechanism of Action Lipolysis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Obesity
Most Recent Events
- 31 May 2005 University of Copenhagen and Aditech Pharma completes a clinical trial in Obesity (In volunteers) (SC) (NCT00259233)
- 31 Mar 2005 Clinical trials in Obesity (In volunteers) (SC) (NCT00259233)